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Salmonella disease are important causes of death among
under-five children in sub Saharan Africa (SSA) [1] with IBI
making up about 10% of all infections [1]. Nontyphoidal
Salmonella (NTS) serovars S. Typhimurium and S. Enteritidis
are among the common causes of IBI in SSA [1,2]. Invasive
NTS (iNTS) is estimated to cause over 2.1 million illnesses
and 416,000 deaths per year [2]. The case fatality rate for NTS
bacteraemia in children exceeds 20%, even with appropriate
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).reaches 52% in young children and 80% in adults [4]. Key
underlying factors of iNTS disease are immature immunity,
malaria infection and malnutrition in children and advanced
HIV infection in adults [3,5e8]. Current or recent Plasmodium
falciparum malaria infections have been shown to be strongly
associated with iNTS, particularly severe malarial anaemia
(SMA) [5,9]. Case fatality rates are higher in children
admitted to hospital with SMA and NTS bacteraemia (24%)
compared to malaria alone (10%) [10,11]. In addition, it is
estimated that 6.5% of IBI occurs in malaria-infected children
[10,11]. In view of the low sensitivity of blood cultures, it has
been suggested that P. falciparum infection could account for
more than 50% of IBI in those children who live in malaria-
endemic settings [6]. Co-infection with malaria and iNTS is
common in febrile children from high malaria transmission
areas compared to those from low malaria transmission areas
[12,9]; conversely typhoid fever is uncommon in febrile
children from high malaria transmission areas [12]. These
findings indicate differences in childhood susceptibility to S.
Typhi and iNTS.eased susceptibility to invasive nontyphoidal Salmonella infection in children
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2 T.S. Nyirenda et al. / Microbes and Infection xx (2017) 1e101.2. Challenges in the clinical management of iNTSFig. 1. Key players of host resistance to Salmonella: Lessons from humans
and mice. Immunity to Salmonella builds up gradually during primary
infection or subclinical exposure to the pathogens. Each level of resistance
adds to the previous one. Therefore, full protection relies on the activity of the
immune mechanisms from each one of the levels of resistance. Co-morbidities
that undermine any of these levels of resistance would result in impaired
overall resistance to iNTS disease.The clinical presentation of NTS bacteraemia is poorly
defined in young children and exhibits clinical overlap with the
presentation of both pneumonia and malaria, posing diagnostic
challenges and highlighting the need for improved diagnostic
tests. iNTS disease typically presents as a febrile systemic
illness similar to enteric fever. Lack of blood culture facilities
and delays in determining aetiological agents remain a chal-
lenge in resource-limited settings. Poorly defined clinical fea-
tures and lack of appropriate diagnostic facilities often results in
children being wrongly diagnosed and treated for malaria
infection while iNTS is unattended, thus leading to poor clinical
outcomes. WHO recommends administration of antimalarial
and antibiotics drugs in children with severe malaria regardless
of proven IBI [11], but antibiotic prescriptions supported by
laboratory findings must be encouraged to prevent further
development of antibiotic resistance. Gordon et al. described
MDR prevalence of NTS in Malawi, defined as resistance to
ampicillin, chloramphenicol, and co-trimoxazole [3]. Currently,
iNTS is treated using third generation cephalosporins and flu-
oroquinolones such as ciprofloxacin are too expensive for
routine use in endemic areas [13].
2. Immunity to iNTS: lessons from humans and animal
models2.1. Spread of ingested Salmonella to distant tissues via
the gastrointestinal tract (GIT)Salmonella infections start with the ingestion of contami-
nated food, water and fomites [14] and then the bacteria reach
the distal ileum or caecum. A proportion of the infectious load
survives the low gastric pH and the competition with normal
flora [15]. Salmonella then invade Microfold (M) cells of the
Peyer Patches (PP) using the Type III secretion system (T3SS)
encoded by the Salmonella pathogenicity island 1 (SPI-1)
[16]. The bacteria reach the blood stream from the GIT either
extracellularly or transported via CD18þ cells [17]. Salmo-
nella can also penetrate the gut epithelial barrier through
dendritic cells (DC) which extend their dendrites between
epithelial cells, overlying villi and capture gut luminal Sal-
monella [18]. Resident macrophages ingest Salmonella in the
PP and mesenteric lymph nodes (MLN). However, virulent
Salmonella may evade macrophage immunity by inducing
macrophage cell death through the SPI-1-encoded Sip B
protein which activates caspase 1 [16]. Salmonella can remain
restricted to the MLN or disseminate via the thoracic duct to
systemic tissues including peripheral blood, spleen, liver and
bone marrow [15].2.2. Phagocytes and host resistance to SalmonellaMonocytes and neutrophils play important roles in con-
trolling Salmonella during the early phase of infection (Fig. 1)
[19,20]. Mice rendered neutropenic by administration of
granulocyte-depleting monoclonal antibodies have beenPlease cite this article in press as: Nyirenda TS, et al., Immunological bases of incr
with malaria and anaemia, Microbes and Infection (2017), https://doi.org/10.1016shown to be more susceptible to Salmonella infection
compared to wild type mice [21]. Neutrophils and monocytes
efficiently ingest Salmonella opsonised by complement factor
C3b, through surface membrane complement receptor 3 (CR3)
[22]. However, non-opsonised Salmonella can also be ingested
by macrophages and neutrophils through CD14 and LPS in-
teractions [23].
Killing of engulfed Salmonella is achieved through meta-
bolic reactions within the phagosome membrane and cytosol
[15]. Phagocytes killing mechanisms include; acidification
(pH ranging 5e4.5), through glucose consumption, generation
of phagolysosomes, generation of reactive oxygen in-
termediates (ROI) and reactive nitrogen intermediates (RNI)
[24,25]. In mice Salmonella growth in the tissues is controlled
by macrophage associated Nramp1 (natural resistance-
associated macrophage protein one) gene (also known as
Slc11a1) during the first few days of infection [26]. Slc11a1
encodes divalent metal (Fe2þ, Zn2þ and Mn2þ) pump phos-
phoglycoproteins, which are recruited to the Salmonella-con-
taining phagosome [15,27]. The importance of ROI in
controlling Salmonella infection is shown by the fact that
chronic granulomatous disease (CGD) patients, whose
phagocytes exhibit defective production of ROI are very sus-
ceptible to infections with intracellular pathogens, including
Salmonella [28].2.3. Role of cytokines and chemokines in immunity to
SalmonellaInnate immune cells such as macrophages, neutrophils and
natural killer cells (NK) produce cytokines that allow co-
ordination of immune responses and subsequent Salmonella
killing (Fig. 1). IL-8 and MIP-1 enhance the recruitment of
leukocytes to the sites of infection [29]. TNF-a promotes
phagocyte recruitment and the generation of multicellular
pathological lesions at the foci of infection. The importance of
TNF-a has been shown in mice treated with anti-TNF-a an-
tibodies or TNFR 55 knockout; these mice fail to restricteased susceptibility to invasive nontyphoidal Salmonella infection in children
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IFN-g is required for the activation and expression of anti-
microbial activity against intracellular Salmonella [31]. NK
cells and gamma-delta T cells are the main producers of IFN-g
in the early stages of the infection as has been shown in Rag 1
knockout mice (lack mature CD4þ T cells, CD8þ T cells and
B cells) which are still capable of producing IFN-g in response
to Salmonella infection [32]. Later in infection IFN-g is pro-
duced by T-cells [33]. Individuals with genetic defects in the
IL-12/IFN-g axis are more susceptible to Salmonella indi-
cating the importance of these cytokines in resistance to Sal-
monella infection in humans [34].2.4. Complement-mediated immunity to SalmonellaComplement is important in controlling Salmonella infec-
tion (Fig. 1) [35]. C1q deficient mice are more susceptible to
infection with S. Typhimurium [35]. Human patients with
sickle cell disease are also more susceptible to Salmonella
bacteraemia compared to healthy controls [36] with the sus-
ceptibility being attributed to reduced serum bactericidal ac-
tivity as a result of defective function of the alternative
complement pathway and low concentration of C3 [37].2.5. T-helper type 1 CD4þ T cell immunity to SalmonellaReduced numbers of CD4 T-cells are associated with
increased susceptibility to systemic Salmonella disease in
animal models [38] or humans (Fig. 1) (e.g. advanced HIV
infection) [39]. Acute Salmonella infection is associated with
increased CD4þ T helper 1 transcriptional factor Tbet and IL-
2, and decreased T helper 2 transcriptional factor Gata 3 and
IL-4 indicating the onset of Th1 immunity [40]. In simian
immunodeficiency virus (SIV) infected macaques (human
HIV infected model), Th17 cells in the ileal mucosa of rhesus
macaques are depleted and this is associated with impaired
mucosal barrier functions (blunted Th17 responses) resulting
in increased systemic dissemination of S. Typhimurium from
the gut [41].2.6. B cell immunity to Salmonella infectionB cells play an important role in protection against Sal-
monella via antibody production (Fig. 1) [42]. The interaction
between CD4þ T cells and B cells is also important for
establishment long-term and robust Th1 type immunity to
Salmonella infection [33,43e45].
Salmonella are facultative intracellular organism and are
capable of surviving in both the extracellular and intracellular
space. Salmonella grow intracellularly and disperse in the
tissues by escaping infected phagocytes and establishing new
infection foci at distant sites [46,47]. This process requires the
T3SS encoded by the Salmonella pathogenicity island 2 (SPI-
2) [48].
In their extracellular phase Salmonella becomes the target
of antibody-mediated immunity [8]. Opsonic IgG or IgM an-
tibodies specific for S. Typhimurium control SalmonellaPlease cite this article in press as: Nyirenda TS, et al., Immunological bases of incr
with malaria and anaemia, Microbes and Infection (2017), https://doi.org/10.1016bacteraemia by activating complement cascade through the
classical pathway which are ultimately killed through mem-
brane attack complex [8]. Opsonic IgG antibodies also control
Salmonella bacteraemia by facilitating neutrophils and
monocytes phagocytosis through their surface membrane FcR
[49] and increasing the production of ROI [50]. T-cells
modulate antibody responses to Salmonella facilitating isotype
switching and being necessary for the production of anti-
protein antibodies [51,52].
In Malawian children antibody-mediated serum killing of
invasive NTS strain occurs in children older than 16 months
and not in younger children [8], indicating a correlation be-
tween NTS-specific antibodies (IgG and IgM) and resistance
[8]. Interestingly, a similar trend (age related development) of
antibody mediated serum immunity to S. Typhi was reported
in children from Nepal [53]. These findings support the
exploration of antibody-based vaccines for NTS bacteraemia.
3. Immunity to malaria: lesson from humans and animal
models3.1. Burden of malariaMalaria is an important cause of morbidity and mortality
especially in children under the age of 5 years. Nearly 214
million clinical episodes of malaria were reported in 2015
leading to 438,000 deaths, the majority of which were among
African children [54]. Although there are four different spe-
cies of the Plasmodium parasite capable of causing disease in
humans, it is P. falciparum which is associated with the
highest morbidity and mortality rates especially in children
aged twelve and less [55].3.2. Plasmodium falciparum life cycleP. falciparum has a complex life cycle with some of the
developmental stages occurring in humans and other stages in
anopheles mosquitos, the vector for the parasite. The cycle
begins when an infected female Anopheline mosquito probes
human skin in preparation for a blood meal (Fig. 2). The saliva
of infectious mosquitos contains sporozoites, a small number
of which, ranging between 10 and 100, are injected into the
skin of the patient where they may remain for hours or days
[56]. The sporozoites then cross the endothelium of the cap-
illaries in the skin, enter the blood and infect the hepatocytes
in the liver [57]. The sporozoites replicate within liver cells,
and differentiate into asexual blood-stage parasites called
merozoites. This stage of the infection is asymptomatic.
Merozoites are then released into the blood stream where they
begin 48 h cycles of invasion of red blood cells (RBCs),
replication, rupturing of RBCs, release of more merozoites
and invasion of new intact RBCs. At this stage parasitemia can
increase to over 50,000 infected RBCs (iRBCs) per microliter
of blood. Different types of parasite components are released
once the iRBCs lyse. The release of these parasite components
is usually associated with the onset symptomatic malaria,
characterized by headaches, fever and lethargy. The parasiteeased susceptibility to invasive nontyphoidal Salmonella infection in children
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Fig. 2. The Plasmodium falciparum life cycle and human host immunity Macrophages, DCs, T cells, and humoral immunity (antibody and complement) are
involved in mounting stage-specific immune responses against the Plasmodium parasite. These are usually divided into either pre-erythrocytic immune responses
directed against sporozoites in the skin and liver-stage parasites, or erythrocytic immune responses, directed against merozoites and intra-erythrocytic parasites.
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further differentiate into male and female gametocytes which
are then ingested by the mosquito and reach the gut when it
feeds on the blood of a human host carrying stage V game-
tocytes [58]. Male and female gametocytes then fuse in the
midgut of the mosquito forming ookinetes which then cross
the midgut epithelium before further differentiating to form
sporozoites that invade the mosquito's salivary glands ready to
be injected into the next human they feed on [58].3.3. The immune systems of humans and mosquitos
mount responses to P. falciparum infectionsIn humans the timing, nature and quality of immune re-
sponses determines the outcome of the disease, whereas in
mosquitoes immunity influences the ability of the vector to
transmit the parasite [59]. Human immune resistance to ma-
laria develops with age and with level of exposure, such that
individuals living in malaria-endemic countries tend to
become resistant to symptomatic malaria, but not to P. fal-
ciparum infection [56]. Immunity is both cellular and
antibody-mediated (Fig. 2) [57], Innate cells, such as mono-
cytes and natural killer (NK) cells and adaptive cells, such as
CD4þ and CD8þ T cells and B cells, are involved in the im-
mune response against the different stages of the parasite cell
cycle and against the development of malaria as a disease [60].3.4. Human immune response against P. falciparumInnate and acquired immune responses against the Plas-
modium parasite are complex and stage-specific. These are
usually divided into either pre-erythrocytic responses directed
against sporozoites in the skin and liver-stage parasites, and
erythrocytic responses, directed against merozoites and intra-
erythrocytic parasites (Fig. 2).Please cite this article in press as: Nyirenda TS, et al., Immunological bases of incr
with malaria and anaemia, Microbes and Infection (2017), https://doi.org/10.10163.5. Immune response against the parasite in the human
skin and in the liverThe initial introduction of sporozoites into the human skin
is merely associated with itching and swelling, but is clinically
not linked to any symptomatic disease or any systemic
inflammation. In addition there is very little, if any, stimulation
of innate immunity in the skin, which in turn, impairs the
subsequent activation of adaptive (CD4þ- and CD8þ-medi-
ated) immunity. This being the case, even after years of
repeated exposure to P. falciparum the risk of adults residing
in malaria-endemic to becoming infected with P. falciparum
parasites is just as high as that of young children [60],
although adults tend to become more resistant to symptomatic
disease. Some investigators have attributed the poor innate
immune response in the skin to the low initial sporozoite
inoculum and the relatively high proportion of regulatory T
cells [61]. It has been suggested that malaria parasites may use
various mechanisms to evade the innate immune system in the
skin, such as the delivery of very small numbers of sporozoites
during the time the infected mosquito feeds on the human,
thus minimizing the activation that the skin-based immune
system [62].3.6. Immune response against blood stage infectionThe merozoites that survive during the pre-erythocytic
stage are responsible for the modification of iRBCs cells in
terms of the array of parasite proteins expressed on the cell
surface and triggering of the immune response against the P.
falciparum parasite, resulting in the clinical manifestations
that characterize malaria [63]. The pathogenic manifestations
associated with severe malaria are thought to be due to pro-
inflammatory cytokines released by T cells and macrophages
in response to malaria parasites and their products, includingeased susceptibility to invasive nontyphoidal Salmonella infection in children
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pigment [64] and Plasmodium-derived nitric oxide synthase
(NOS)-inducing factor [65].
Antibody-mediated responses against extracellular merozo-
ites and intraerythrocytic parasites have previously been regar-
ded as the most fundamental component of erythrocytic stage
immunity, with their beneficial roles first demonstrated by the
therapeutic effects of the passive transfer of adult immune IgG to
infected children in the sixties [66]. An antibody binding to the
surface of the merozoite and to proteins that are externalized
from the apical complex of organelles involved in erythrocyte
recognition and invasion, has been reported to have an important
role in immunity to asexual blood stages. This antibody could
neutralize parasites or lead to Fc dependent mechanisms of
parasite killing by macrophages [67]. To date little is known
about T cell responses against iRBCs, partly because erythro-
cytes lack MHC class I or class II presentation capacity.
Nevertheless, cellular responses against iRBC have been sug-
gested to contribute to protection in humans in the absence of
antibodies [68,69]. In addition, monocyte/macrophage-mediated
responses, in particular phagocytosis and antibody-dependent
cellular inhibition, also form an important component of
blood-stage immunity [70]. IFN-g is now known to play a crucial
role in immunity against blood-stage Plasmodium parasites and
requires coordinated and timely innate and adaptive immune
responses involving dendritic cells (DC), NK cells, CD4þ T
helper cells, and B cells [70]. With the pathogenesis associated
with severe malaria thought to be linked to unregulated pro-
duction of pro-inflammatory cytokines, the balance between pro-
inflammatory and anti-inflammatory responses is therefore
essential to limit the development of life-threatening immune-
mediated pathology such as cerebral malaria (CM) and SMA. A
better understanding of regulatory mechanisms required to
maintain the balance between beneficial and deleterious re-
sponses during blood-stage malaria infection remains elusive but
would be extremely useful in the prevention of severe malaria
[71].
4. Mechanisms of increased susceptibility to iNTS in
children with malaria and anaemia4.1. Malaria-related impairment of gut barrier defences
to NTSThe gut barrier provides the first line of defence to iNTS.
Gut mucosal resistance to NTS is complex, potentially
involving of both cellular and humoral arms of immunity, the
gut epithelial layer and microbiota. From histological studies
it has long been known that the sequestration of malaria par-
asites to the gut is common in humans [72]. Intestinal fatty
acid binding protein (IFABP), a biomarker of intestinal barrier
ischemia, is elevated in malaria-infected children and this is
associated with increased malaria-infected RBC binding to
ICAM [73]. In malaria-infected mice, L-arginine deficiency
has been reported to mediate the disruption of the intestinal
barrier [74]. Alterations in the gut barrier during malaria havePlease cite this article in press as: Nyirenda TS, et al., Immunological bases of incr
with malaria and anaemia, Microbes and Infection (2017), https://doi.org/10.1016been reported to promote microbial translocation from gut to
the bloodstream (Fig. 3) [74,75]. Recently, in malaria-infected
mice, it has been shown that inflammation mediates changes in
the gut microbiota, leading to increased colonization of the gut
by NTS [76]. It is still unclear how different clinical forms of
malaria affect the gut barrier to NTS.4.2. Malaria-related compromise of complement
mediated immunity to NTSComplement consumption is known to occur in acute ma-
laria (Fig. 3) [77,78]. The levels of complement components
return to normal during convalescence. Classical pathway
components including C1q, C4, C3 are particularly reduced
during malaria and this leads to reductions in complement
dependent-antibody mediated NTS killing in children [79].
Loss in complement mediated cell-free killing during malaria
occurs in children regardless of high antibody titre to LPS [79].
Malaria-induced complement consumption may contribute to
reductions in phagocytosis and phagocytes-mediated killing via
ROI but this remains to be fully explored in humans. Further-
more, others have shown that complement consumption is
higher in severe malaria compared to uncomplicated malaria
[77,78]. However, the relationship between complement con-
sumption in various clinical forms of malaria and susceptibility
to iNTS has not been explored.4.3. Malaria-related impairment of phagocytes effector
functions to NTSMalaria-derived products have been shown to compromise
the effector functions of neutrophils, monocytes and macro-
phage in humans and animals [80e82]. Uptake of malaria-
infected RBC and hemozoin renders monocytes unable to
degrade the internalised products and reduces their phagocytic
functions (Fig. 3) [81]. Robust production of ROI does not
occur in phagocytes following the ingestion of malaria-derived
products (Fig. 3) [81]. In line with this, hemozoin has been
implicated in the suppression of the function of NADPH ox-
idase in human monocyte-derived macrophage via inhibition
of PKC [82]. Malaria-mediated hemolysis releases hemoglo-
bin and increases the levels of hemoglobin-derived heme. The
latter induces heme oxygenase-1 (HO-1) in immature myeloid
cells; heme is further degraded to biliverdin, carbon monoxide
and iron. Heme degradation products in chronic hemolysis
drive the release of functionally immature granulocytes from
the bone marrow into the blood and these immature phago-
cytes have reduced ability to produce ROI and are thus less
efficient at controlling bacterial infections including NTS
[80,83].4.4. Malaria-related cytokine changes favouring the
proliferation of NTSMalaria induces the elevated levels of anti-inflammatory
IL-10, which plays a role in avoiding malaria-related tissueeased susceptibility to invasive nontyphoidal Salmonella infection in children
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Fig. 3. Malaria and anaemia increase susceptibility to iNTS in children. Healthy children are capable of restricting NTS colonisation and invasion within the
gastro-intestinal tract (GIT) through due to their normal flora and efficient epithelial barrier (Fig. 3A). Malaria can impair the gut-epithelial barrier, thus favouring
NTS translocation to the blood stream (Fig. 3B). Humoral (antibody and complement) and cellular (monocytes and neutrophils) immunity to NTS can be
compromised due to malaria-induced anaemia, products from malaria parasites and also immune responses to malaria parasites which concomitantly favour the
proliferation and dissemination of NTS (Fig. 3C).
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IL-10 has been shown in animal studies to exacerbate bacterial
infections including salmonellosis [84,85]. In severe malaria
anaemia increased production of IL-10 has been implicated in
down-regulating the production of IL-12. Lower levels of IL-
12 have been shown to favour the growth of microbes such as
NTS (Fig. 3) [86,87]. This anti-inflammatory environment
favourable for the growth of NTS occurs within the gastro-
intestinal tract and systemic circulation [84,85]. The impact
of malaria related anti-inflammatory responses on suscepti-
bility to iNTS has not been investigated in endemic settings.4.5. Malaria and non-malaria related anaemia favours
the proliferation of NTSEpidemiological studies have shown that malaria, particu-
larly severe malaria anaemia, is a key risk factor for iNTS
[36,11]. Malaria-induced destruction of iRBC allows the
release of iron and heme, which promote intracellular bacterial
growth and inhibit the effector functions of phagocytes
respectively (Fig. 3) [88,80,89]. Individuals with sickle cell
anaemia are more susceptible to Salmonella bacteraemia and
this susceptibility appears to be mediated by defectivePlease cite this article in press as: Nyirenda TS, et al., Immunological bases of incr
with malaria and anaemia, Microbes and Infection (2017), https://doi.org/10.1016complement immunity particularly the alternative pathway
[37,90].4.6. Age-related susceptibility to iNTSYoung children below the age of 2 are more susceptible to
iNTS disease in endemic settings [7] with peak susceptibility
around 13 months of age. The peak incidence of iNTS disease
coincides low titres of antibodies, suggesting that antibodies
play a crucial role in controlling NTS infection [7,8].4.7. Natural and vaccine-acquired memory B cell and
antibody responses to Salmonella during malariaIn malaria-endemic regions it has long been suspected that
P. falciparum infection reduces vaccine efficacy in children
[91]. Most licensed vaccines confer protection through anti-
bodies [92]. Long-lived antibody responses depend on mem-
ory B cells (MBCs) and long-lived plasma cells (LLPCs) [93].
In mice, malaria-mediated apoptosis has been implicated to
loss of memory B and plasma cells [94]. Whether this con-
tributes to the suppression of pre-existing antibody responses
remains to be explored.eased susceptibility to invasive nontyphoidal Salmonella infection in children
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antibody responses to polysaccharide vaccine antigens while
evidence on suppression of antibody responses to vaccine
protein antigens is weak [95]. We found in Malawian children
that levels of pre-existing IgG antibodies targeting NTS-LPS
were similar during acute malaria, at days 14 and 30 malaria
convalescence compared to age match healthy controls [79]. In
line with this, mice immunized with live attenuated Salmo-
nella vaccine had similar levels of antibody titres pre and post
malaria infection [96]. GMMA and new generations of
glycoproteins-based NTS vaccines are currently in the pre-
clinical phase of evaluation [97,98]. Field studies are
required to gain better understanding of the effect of malaria
on NTS-specific vaccine responses currently in pre-clinical
phase; this is a crucial step in the development of these new
vaccines aimed to be implemented in settings where malaria is
endemic.4.8. Vaccine-acquired memory CD4þ T cell and effector
function to Salmonella during malariaStrong evidence on how malaria suppresses vaccine
induced memory CD4þ T cell immune responses to NTS
comes from mice model of malaria and NTS co-infection.
Protective immune responses to NTS conferred by live
attenuated Salmonella vaccine is lost following challenge with
non-lethal Plasmodium yoelii 17XNL coinfection [96]. This
loss in protection to NTS is associated with increased levels of
IL-10 and Salmonella specific effector CD4 T cell responses
are reduced [96]. Blocking IL-10 with antibodies partially
restored protection to NTS. Other key contributors to this
malaria-related susceptibility to NTS include increased
expression of CTLA-4, LAG3 and PD1 on CD4þ T cells [96].
5. Strategies to overcome malaria and iNTS disease in
children5.1. Prevention of both malaria and iNTSIn SSA, where both malaria and iNTS are endemic, pre-
vention of these fatal diseases through vaccination has not
been possible due to the delay in vaccine development. The
RSTS,S malaria vaccine has shown promising results in clin-
ical studies. It is anticipated that when this vaccine is imple-
mented, it will supplement existing malaria reduction
strategies including early treatment of malaria cases with
artemisinin-based combination therapies (ACTs), indoor re-
sidual spraying (IRS), long-lasting insecticide treated bed nets
(LLINS) and intermittent treatment therapy for pregnant
women (IPTp). As observed in some countries that have
experienced epidemiological changes in the incidence of ma-
laria and iNTS disease, we anticipate that following the rollout
of malaria vaccines, cases of iNTS will be reduced in endemic
settings. It will take several years before the implementation of
a vaccine against iNTS disease as most candidates are still at
the pre-clinical phase [98].Please cite this article in press as: Nyirenda TS, et al., Immunological bases of incr
with malaria and anaemia, Microbes and Infection (2017), https://doi.org/10.10165.2. Population tailored interventionsWHO guidelines recommend the administration of both
anti-malaria drug and antibiotic in case of severe malaria in
children without evidence of concurrent invasive microbial
infection [11]. This recommendation is widely accepted by
researchers on malaria and bacterial co-infections. However,
improvements on this recommendation are necessary as field
studies are showing that even uncomplicated malaria renders
children susceptible to invasive bacterial infections [79].
Revised guidelines that will also cover uncomplicated malaria
and bacterial infection are warranted. Field epidemiological
studies have also suggested that malaria plays a role in the
poor vaccine efficacy observed in malaria endemic areas.
Recommendations by other investigators to avoid childhood
vaccination during malaria episodes and only administer
vaccines when malaria has been cleared have not materialised
probably due to limited scientific evidence supporting these
recommendations. In regions where NTS colonization is
endemic, iron supplementation to address malaria or non-
malaria induced anaemia should be administered with
caution to avoid creating favourable niche for the growth of
microbes such as NTS. The use of adjunct therapy in order to
correct factors that promote NTS growth such as HO-1 needs
to be explored further in field settings.5.3. Field studiesRecent evidence from field studies that malaria compro-
mises both the humoral and cellular immunity is interesting
[79]. While several studies have focussed on the malaria-
induced compromise of the cell mediated host immunity,
studies on malaria-related impairment of humoral immunity
are limited. We particularly recommend field studies to
establish reference levels of complement in various forms of
malaria and also areas of malaria endemicity. Such studies will
help to inform immunological interventions to correct malaria
induced hypocomplentaemia.
6. Conclusion
Malaria has consistently been shown to be a major risk
factor for iNTS disease in African children. Knowledge of
clinical and epidemiological risk-factors for iNTS disease has
not been paralleled by an in depth knowledge of the immu-
nobiology of the disease. Our understanding of resistance/
susceptibility to iNTS in Africa is further complicated by
overlapping risk factors/comorbidities such as young age,
malaria and anaemia that often coexist in the same individual
or in the same endemic area, and create complex clinical
scenarios for the understanding of immunity and the evalua-
tion of protection.
Although modification of susceptibility factors is impor-
tant, vaccines against iNTS for African children are a high
priority in settings with very limited health systems, but their
development is challenging. Both the quality of response, andeased susceptibility to invasive nontyphoidal Salmonella infection in children
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8 T.S. Nyirenda et al. / Microbes and Infection xx (2017) 1e10antigen targets need to be optimised to confer a sufficient level
of protection, even in children whose innate immunity may be
impaired by widespread comorbidities such as malaria and
anaemia.
Therefore better knowledge of how host effector immuno-
logical mechanisms interact to control the growth and kill
iNTS in humans in the setting of co-morbidities such as ma-
laria is absolutely essential for vaccine development against
iNTS in Africa.
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